The Glypican 3 pipeline drugs market research report outlays comprehensive information on the Glypican 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Glypican 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Hepatocellular Carcinoma, and Solid Tumor. It also reviews key players involved in Glypican 3 targeted therapeutics development with respective active and dormant or discontinued products.
The Glypican 3 pipeline targets constitutes close to eight molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 2, and 1 respectively. Similarly, the universities portfolio in Phase I comprises 2 molecule.
Glypican 3 overview
Glypican 3 (GPC3) is a cell surface proteoglycan. It comprises of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. By binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands it regulates the canonical Wnt signaling pathway positively. It binds to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types.
For a complete picture of Glypican 3’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
